Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 107-114

  Ellis, P ^a   Smith, I ^a   Ashley, S ^a   Walsh, G ^a   Ebbs, S ^a   Baum, M ^a   Sacks, N ^a   McKinna, J ^a  

^a Royal Marsden Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN; MITOXANTRONE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0031982870     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.107     Document Type: Article

References (29)

1. Anderson ED, Forrest AP, Hawkins RA, et al: Primary systemic therapy for operable breast cancer. Br J Cancer 63:561-566, 1991
2. Bonadonna G, Valagussa P, Zucali R, et al: Primary chemotherapy in surgically resectable breast cancer. CA Cancer J Clin 45:227-243, 1995
3. Smith IE, Walsh G, Prendiville J, et al: High complete remissions with primary int'usional chemotherapy for large early breast cancer. J Clin Oncol 13:424-429, 1995
4. Powles TJ, Hickish TF, Makris A, et al: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13:547-552, 1995
5. Fisher B: Pre-operative chemotherapy: A model for studying the biology and therapy of primary breast cancer. J Clin Oncol 13:537-538, 1995
6. Fisher B, Rockette H, Robidoux A: Effect of preoperative therapy for breast cancer on locoregional disease: First report of NSABP B-18. Proc Am Soc Clin Oncol 13:64, 1994 (abstr)
7. Mauriac L, Durand M, Avril A, et al: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2:347-354, 1991
8. Scholl SM, Fourquet A, Asselain B, et al: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6. Eur J Cancer 30A:645-652, 1994 (suppl)
9. Semiglazov VF, Topuzov EE, Bavli JL, et al: Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 5:591-595, 1994
10. Forrest AP, Levack PA, Chetty U, et al: A human tumour model. Lancet 2:840-842, 1986
11. Ferriere JP, Assier I, Cure H, et al: Primary chemotherapy in breast cancer (BC): Correlation between tumour response and outcome. Proc Am Soc Clin Oncol 15:105, 1996 (abstr)
12. Botti C, Vici P, Lopez M, et al: Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast. J Am Coll Surg 181:202-208, 1995
13. McCready DR, Hortabagyi GN, Shu WK, et al: The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg 124:21-25, 1988
14. Gardin G, Rosso R, Campora E, et al: Locally advanced non-metastatic breast cancer: Analysis of prognostic factors in 125 patients homogenously treated with a combined modality approach. Eur J Cancer 31A:1428-1433, 1995
15. Smith IE, Jones AL, O'Brien MER, et al: Primary medical (neoadjuvant) chemotherapy for operable breast cancer. Eur J Cancer 29A:1796-1799, 1993
16. Miller AB, Hoogstraten B, Straquet M: Reporting results of cancer treatment. Cancer 147:207-214, 1981
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
18. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomised clinical trials requiring prolonged observation of each patient: Analysis and examples. B J Cancer 35:1-39, 1976
19. Tarone R: Tests for trend in lifetable analysis. Biometrika 62:679-682, 1975
20. Cox DR: Regression models and life tables. J R Stat Soc 34:187-220, 1972
21. American Joint Committee: Breast Cancer, Manual for Staging of Cancer. Philadelphia, PA, Lippincott 1992, pp 149-154
22. Calais G, Berger C, Descamps P: Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer 74:1283-1288, 1994
23. Scholl SM, Pierga JY, Asselain B: Breast tumour response predicts local and distant control as well as survival. Eur J Cancer 12:1969-1975, 1995
24. Schwartz GF, Birchansky CA, Komarnicky LT, et al: Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 73:362-369, 1993
25. Fisher B, Brown A, Mamounas E, et al: Effect of pre-operative therapy for primary breast cancer on loco-regional disease, disease-free survival, and survival: results of NSABP B-018. Proc Am Soc Clin Oncol 16:(A449)127, 1997 (abstr)
26. Haagensen CD, Stout AP: Carcinoma of the breast: Criteria of operability. Ann Surg 118:1259-1265, 1943
27. Bernardo G, Plastina M, Bernardo G, et al: Neoadjuvant chemotherapy (cyclophosphamide, epirubicin and fluoracil) plus G-CSF for operable breast cancer. Proc Am Soc Clin Oncol 14:A201, 1995 (abstr)
28. Chollet P, Charrier S, Brain E, et al: High pathological response rate induced by intensive anthracycline-based regimen. Proc Am Soc Clin Oncol 14:A218, 1995 (abstr)
29. Veronesi U, Bonadonna G, Zurrida S, et al: Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 222:612-618, 1995